Prerequisites to improvement of predictive model of childhood Hodgkin’s lymphoma

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access


Background. Calculation of relative tumor burden in Hodgkin’s lymphoma patients is the simplest and significant parameter which can be used in daily clinical practice as a risk factor. The aim of study was the assessment of influence of relative tumor burden on the late results of a disease. Material and methods. This research included data on 126 patients with Hodgkin’s lymphoma aged from 0 till 18 years (middle age of 11 years), treated risk-adapted treatment according to the DAL-HD and SPBLH-05. Boys was 70, girls - 56 (a ratio 1,25 : 1). Fifty-eight patients (46 %) are stratified in favorable risk group, 50 (39,7 %) - in intermediate risk group, and 50 (39,7 %) are included in unfavorable risk group. Results. Overall survival at 5 years was 93 % (range 91-95 %), event-free survival - 88 % (85-91 %). The average relative tumor burden was 129,4 cm3/m2 (7-609,7 cm3/m2). When carrying out ROC-analysis value of 122,7 cm3/m2 (р ˂ 0,0001) appeared the critical parameter, which worsen the prognosis of a disease. Overall survival in a patients cohort with this volume was 69,6 %, with the volume less than 122,7 cm3/m2 overall survival was 97,2 % (р = 0,00002). Conclusions. The relative tumor burden is the parameter which is significantly reducing survival rates in children with Hodgkin’s lymphoma. Opinion on interrelation of clinical and laboratory parameters with “sarkoma’s saturation” or tumor volume as end result of immunological frustration, it is represented the most perspective direction of studying of Hodgkin’s lymphoma.

Full Text

Restricted Access

About the authors

Svetlana Aleksandrovna Kulyova

N.N. Petrov Research Institute of Oncology

MD, PhD, Dr Med Sci, Professor, Head. Department of Children`s Chemotherapy and Combined Modality Therapy

Andrei Petrovich Karitsky

N.N. Petrov Research Institute of Oncology

MD, PhD, Head. Hospital

Svetlana Viacheslavovna Ivanova

N.N. Petrov Research Institute of Oncology

Department of Children`s Chemotherapy and Combined Modality Therapy


  1. Колыгин Б. А., Кулева С. А. Диагностика и лечение лимфомы Ходжкина. СПб.: Гиппократ; 2009.
  2. Baker K. S., Gordon B. G., Gross T. G., Abromowitch M. A., Lyden E. R., Lynch J. C. et al. Autolgous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J. Clin. Oncol. 1999; 17: 825-31.
  3. Gobbi P. G., Bergonzi M., Bassi E., Merli F., Coriani C., Stelitano K. et al. Tumor burden in Hodgkin’s lymphoma can be reliably estimated from a few staging parameters. Oncology reports. 2012; 28: 815-20.
  4. Gobbi P. G., Broglia C., Giulio G. et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer. 2000; 101: 1824-34.
  5. Gobbi P. G., Comelli M., Grignani G. E. et al. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). Haematologica. 1994; 79: 241-55.
  6. Gobbi P. G., Ghirardelli M. L., Solcia M. et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J. Clin. Oncol. 2001; 19: 1388-94.
  7. Hasenclever D., Diehl V. A prognostic score to predict tumor control in advanced Hodgkin's disease.N. Engl. J. Med. 1998; 339: 1506-14.
  8. Horning S. J. Risk, cure and complications in advanced Hodgkin disease. Hematology Am. Soc. Hematol. Educ. Program. 2007: 197-203.
  9. Kulyova S. A., Kochurova N. V., Kolygin B. A. DAL-HD as a risk-adapted treatment of children with Hodgkin’s lymphoma. HAEMA. 2006; 8 (1): 98-104.
  10. Kulyova S. A., Kochurova N. V., Kolygin B. A. VBVP (Viblastine, Bleomycin, VP-16 and Prednisolone) in treatment for childhood Hodgkin’s lymphoma. HAEMA. 2005; 8 (1): 78-82.
  11. Kulyova S. A., Kolygin B. A. Hodgkin’s lymphoma in children and adolescents: a Saint Petersburg Hodgkin’s Lymphoma Group Study. J. Oncol. 2011. Available at:
  12. Schellong G., Pötter R., Brämswig J., Wagner W., Prott F. J., Dörffel W. et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: the German-Austrian Multicenter Trial DAL-HD-90. J. Clin. Oncol. 1999; 17 (12): 3736-44.
  13. Schellong G., Brämswig J. H., Hörnig-Franz I., Schwarze E. W., Pötter R., Wannenmacher M. Hodgkin’s disease in children: combined modality treatment for stages IA, IB and IIA. Ann. Oncol. 1994; 5 (2): 113-5.
  14. Specht L. Tumor burden as the main indicator of prognostic in Hodgkin’s disease. Eur. J. Cancer. 1992; 28: 1982-5.
  15. Specht L., Nissen N. I. Hodgkin’s disease and stage. Eur. J. Haematol. 1989; 43: 127-35.
  16. Specht L., Nissen N. I. Prognostic factors in Hodgkin’s disease stage III with special reference to tumour burden. Eur. J. Haematol. 1988; 41: 80-7.
  17. Specht L., Nissen N. I. Prognostic factors in Hodgkin’s disease stage IV. Eur. J. Haematol. 1988; 41: 359-67.
  18. Specht L., Nissen N. I. Prognostic significance of tumour burden in Hodgkin’s disease PS I and II. Scand. J. Haematol. 1986; 36: 367-75.
  19. Specht L., Nordentoft A. M., Cold S. et al. Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988; 61: 1719-27.
  20. Specht L., Lauritzen A. F., Nordentoft A. M. et al. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group. Cancer. 1990; 65: 2594-601.
  21. Straus D. J., Gaynor J. J., Myers J. et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J. Clin. Oncol. 1990; 7: 1173-86.
  22. Zweig M. H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chemistry. 1993; 39: 561-77.



Abstract - 390

PDF (Russian) - 268


Article Metrics

Metrics Loading ...



Copyright (c) 2015 Kulyova S.A., Karitsky A.P., Ivanova S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies